Commentary|Videos|November 20, 2026

Dr dos Anjos on How Access and Cost Shape Breast Cancer Treatment in Brazil

Bridging the Gaps in Breast Cancer

Carlos Henrique dos Anjos, MD, discussed how drug access and cost influenced HER2-positive breast cancer treatment choices in Brazil.

“In Brazil, we have [a proportion] of patients are treated in the public system, and unfortunately those patients have poor access to the new drugs. And when I talk about new drugs, [these are] new drugs that are old in the United States.”

Carlos Henrique dos Anjos, MD, a medical oncologist at Hospital Sírio-Libanês, discussed how differences in drug access and cost influence breast cancer treatment selection in Brazil, particularly when clinicians considered newer HER2-directed regimens.

Anjos described a divide between the public and private health care systems in Brazil, explaining that patients receiving public care often had limited access to treatments that had already been available in the United States for years. As an example, he noted that CDK4/6 inhibitors, which are parts of standards of care in hormone receptor (HR)–positive breast cancer management in the United States, remain unavailable in many parts of Brazil.

For HER2-positive breast cancer, he described access to trastuzumab (Herceptin) and pertuzumab (Perjeta) in the public system, but said fam-trastuzumab deruxtecan-nxki (Enhertu; T-DXd) and ado-trastuzumab emtansine (Kadcyla) are unavailable there in the metastatic setting. By contrast, he estimated that the private sector covers approximately one-quarter of the population and generally offered treatments similar to those used in the United States.

Turning to the treatment selection, Anjos explained that clinicians in Brazil and other countries with constrained resources often incorporate cost effectiveness into their decisions. For example, for patients with HR-positive and HER2-positive advanced disease, he compared the first-line T-DXd plus pertuzumab approach studied in the phase 3 DESTINY-Breast09 trial (NCT04784715) vs a strategy informed by the phase 3 PATINA trial (NCT02947685) involving trastuzumab, pertuzumab, and palbociclib (Ibrance), noting that biosimilars are available for agents like trastuzumab and pertuzumab. He suggested that these differences could influence a physician’s choice when more than one clinically reasonable option was available. However, he did not present lower cost as the overriding priority for every patient. For patients with brain metastases, he suggested that the DESTINY-Breast09 approach would probably remain the preferred option.

His discussion emphasized the practical distinction between having several effective regimens available and being able to provide them within a particular health system. Anjos framed cost-effectiveness as information that clinicians could use when selecting between suitable options, while retaining attention to the patient’s clinical circumstances. He described these considerations as part of everyday treatment selection in Brazil, where the availability of individual agents differed substantially according to whether patients received care through the public system or the private sector.


Related to this article